Commentary|Videos|December 9, 2025
Decoding Developments in GVHD Management With Drs Salhotra and Negrin
Amandeep Salhotra, MD, and Robert Negrin, MD, sit down with Chandler Park, MD, FACP, to discuss the latest abstracts in graft-vs-host disease presented during the 2025 ASH Annual Meeting & Exposition.
Advertisement
Amandeep Salhotra, MD, of City of Hope, and Robert Negrin, MD, of Stanford Medicine, sit down with Chandler Park, MD, FACP, of Norton Cancer Institute, to discuss the latest abstracts in graft-vs-host disease presented during the 2025 ASH Annual Meeting & Exposition.
Advertisement
Related to this article
Romiplostim N01 supported platelet engraftment after unrelated umbilical cord blood transplantation with no serious TRAEs in hematologic malignancies.
The FDA approved Orca-T for use in matched donor HSCT with a myeloablative preparative regimen in hematological malignancies.
IV ST-001 nanoFenretinide produced a 28% response rate in heavily pretreated cutaneous T-cell lymphoma in a first-in-human phase 1a trial.
In an MAIC, mogamulizumab led to an OS improvement vs vorinostat in patients with relapsed/refractory mycosis fungoides or Sézary syndrome.
Distinct somatic mutation profiles separated responders from non-responders to mogamulizumab in mycosis fungoides and Sézary syndrome.
Maintenance with chidamide and azacitidine generated high 3-year overall survival and a low relapse incidence in high-risk AML after allogeneic transplant.
Both annamycin-containing arms produced numerically higher CR and CRc rates vs cytarabine alone in relapsed/refractory AML.
The top 5 OncLive TV videos of the week cover insights in breast cancer, lymphoma, melanoma, prostate cancer, and ovarian cancer.
Advertisement
Advertisement
Trending on OncLive
1
Dr Orloff on Key Findings From the Phase 2/3 OptimUM-02 Trial in Uveal Melanoma
2
Belantamab Mafodotin Yields Sustained MRD Negativity in R/R Myeloma
3
Study Identifies RNA Surveillance Defect That Fuels Melanoma Through Endogenous Retroviral RNA
4
Luspatercept Sustains Long-Term Transfusion Independence, Favorable OS Trend in ESA-Naive Lower-Risk MDS
5